presentation by Mauro Petretta, Senior Scientific Advisor, REGENHU
In this talk, I will give a brief overview of REGENHU, 3D bioprinting applications, from drug discovery to tablet formulation, and examples of how our partners have advanced their research using our instruments.
What drives you?
Bioprinting is a discipline with enormous potential to positively impact healthcare. The fact that we can help support researchers in developing breakthrough treatments to help those who need it most is a huge driver for me.
Why should the delegate attend your presentation?
The aim of this talk to create more awareness of bioprinting, an ever-evolving discipline still in its infancy, its many applications across a wide range of fields, and how REGENHU’s bioprinting technologies can help researchers & scientist across all domains achieve their research objectives.
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
Bioprinting technologies provide new, disruptive approaches that could enable paradigm shifts in a wide range of healthcare applications. While the biofabrication of functional, complete tissues and organs for clinical regenerative medicine applications represents a goal still requiring some time to be achieved, other fields such the use of bioprinted tissue models for drug discovery applications and the fabrication of custom-made solid dosage forms for personalized treatments could already represent a promising alternative in the immediate future.
What kind of impact do you expect them to have?
Bioprinting technologies present the potential to have a tremendous impact in healthcare. The possibilities are endless, from animal-free, ethical approaches to drug testing with increased performance and no tissue availability issues to the implementation of point-of-care, patient-specific therapeutic treatments in which all the required active compounds are delivered in a single tablet, with tunable and independent release profiles. The fabrication of bioprinted tissues and organs will also clearly represent a groundbreaking innovation in the field of regenerative medicine, allowing to get rid of all the hurdles concerning donor availability and immune responses related to transplants. In addition, also applications like the fabrication of bio-MEMS and organ-on-chips are starting to explore the promising advantages of biofabrication techniques.
What are the barriers that might stand in the way?
Despite of the enormous potential and promises they hold, bioprinting technologies still present several limitations that need to be solved in order to implement these approaches in clinical practice. While there have been huge advances made by research groups all over the world, we are still unable to completely mimic the complexity and functions of native tissues. For this reason, it’s still important to invest in technological improvements that could help overcome these challenges. Moreover, there are still limitations concerning the regulatory framework concerning the use of this technique.
Mauro Petretta is the Senior Scientific Advisor at REGENHU and is responsible for the development of scientific applications using our platform. His work focuses on the processing of biomimetic and functionalized biomaterials, ranging from polymeric composite to cell-laden hydrogels, through additive manufacturing technologies for use in fields of hard and soft tissue regeneration, drug discovery, personalized pharmaceuticals or bioelectronics. He brings years of research experience on tissue engineering and regenerative medicine combined with an in-depth know-how of REGENHU’s bioprinting platforms.
REGENHU is a research driven, Swiss MedTech bioprinter pioneer committed to assisting the research and scientific communities by creating and developing state-of-the art bioprinting technologies to revolutionize medicine. Founded in 2007, the dynamic and rapidly expanding company is based in Villaz-St-Pierre, Switzerland, with offices in the United States, and distributors in Asia and Oceania.
Wai Yee Yeong will be speaking at the conference.